{"transactions":[{"id":12328,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-03-03T23:14:39.000Z","date":"2026-02-27","kind":"tax_withholding","planned":false,"acquired":false,"shares":8037,"price":232.08,"value":1865226.96,"ownership":{"direct":true},"balance_after":52376,"source":{"system":"sec-edgar","filing":"0002004979-26-000004","document":"form4-03032026_110334.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000200497926000004/form4-03032026_110334.xml","form_type":"4"}},{"id":13211,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Option (Right to buy)","published_at":"2026-02-20T23:36:48.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":21937,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,313 on February 18, 2027, 7,312  on February 18, 2028, and 7,312 on February 18, 2029."}],"balance_after":21937,"derivative":{"exercise_price":230.04,"expiration_date":"2036-02-17","underlying":"Common Stock","underlying_shares":21937},"source":{"system":"sec-edgar","filing":"0002004979-26-000002","document":"form4-02202026_110244.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000200497926000002/form4-02202026_110244.xml","form_type":"4"}},{"id":13210,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:36:48.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":6638,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":60413,"source":{"system":"sec-edgar","filing":"0002004979-26-000002","document":"form4-02202026_110244.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000200497926000002/form4-02202026_110244.xml","form_type":"4"}},{"id":13209,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:36:48.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":3346,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":53775,"source":{"system":"sec-edgar","filing":"0002004979-26-000002","document":"form4-02202026_110244.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000200497926000002/form4-02202026_110244.xml","form_type":"4"}},{"id":13208,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:36:48.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":2138,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":50429,"source":{"system":"sec-edgar","filing":"0002004979-26-000002","document":"form4-02202026_110244.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000200497926000002/form4-02202026_110244.xml","form_type":"4"}},{"id":13207,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock, $0.01 par value","published_at":"2026-02-20T23:36:48.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":6015,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026."}],"balance_after":48291,"source":{"system":"sec-edgar","filing":"0002004979-26-000002","document":"form4-02202026_110244.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000200497926000002/form4-02202026_110244.xml","form_type":"4"}},{"id":26179,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-03-04T22:00:28.000Z","date":"2025-02-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":4678,"price":205.02,"value":959083.56,"ownership":{"direct":true},"balance_after":42276,"source":{"system":"sec-edgar","filing":"0001415889-25-006587","document":"form4-03042025_050323.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588925006587/form4-03042025_050323.xml","form_type":"4"}},{"id":28001,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Option (Right to buy)","published_at":"2025-02-18T22:00:21.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,334 on February 13, 2026, 8,333 on February 13, 2027, and 8,333 on February 13, 2028."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,334 on February 13, 2026, 8,333 on February 13, 2027, and 8,333 on February 13, 2028."}],"balance_after":25000,"derivative":{"exercise_price":192.86,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-25-004463","document":"form4-02182025_050218.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588925004463/form4-02182025_050218.xml","form_type":"4"}},{"id":28000,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-02-18T22:00:21.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":3348,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025."}],"balance_after":46954,"source":{"system":"sec-edgar","filing":"0001415889-25-004463","document":"form4-02182025_050218.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588925004463/form4-02182025_050218.xml","form_type":"4"}},{"id":27999,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-02-18T22:00:21.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":2138,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025."}],"balance_after":43606,"source":{"system":"sec-edgar","filing":"0001415889-25-004463","document":"form4-02182025_050218.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588925004463/form4-02182025_050218.xml","form_type":"4"}},{"id":27998,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-02-18T22:00:21.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":1474,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025."}],"balance_after":41468,"source":{"system":"sec-edgar","filing":"0001415889-25-004463","document":"form4-02182025_050218.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588925004463/form4-02182025_050218.xml","form_type":"4"}},{"id":27997,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-02-18T22:00:21.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":3595,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025."}],"balance_after":39994,"source":{"system":"sec-edgar","filing":"0001415889-25-004463","document":"form4-02182025_050218.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588925004463/form4-02182025_050218.xml","form_type":"4"}},{"id":28568,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Option (Right to buy)","published_at":"2025-02-07T21:00:13.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":13868,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,775 on February 15, 2025, 7,775 on February 15, 2026, and 7,774 on February 15, 2027."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Due to an administrative error the exercise price for options awarded February 15, 2024 was previously reported as $0 but the correct value of $175.28 is reflected in this amendment."}],"balance_after":13868,"derivative":{"exercise_price":175.28,"exercise_date":"2025-02-15","expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":13868},"source":{"system":"sec-edgar","filing":"0001415889-25-003337","document":"form4a-02072025_040201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588925003337/form4a-02072025_040201.xml","form_type":"4/A","original_submission_date":"2024-02-20"}},{"id":28567,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-02-07T21:00:13.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":2140,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024."}],"balance_after":41313,"source":{"system":"sec-edgar","filing":"0001415889-25-003337","document":"form4a-02072025_040201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588925003337/form4a-02072025_040201.xml","form_type":"4/A","original_submission_date":"2024-02-20"}},{"id":28566,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-02-07T21:00:13.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":1476,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024."}],"balance_after":39173,"source":{"system":"sec-edgar","filing":"0001415889-25-003337","document":"form4a-02072025_040201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588925003337/form4a-02072025_040201.xml","form_type":"4/A","original_submission_date":"2024-02-20"}},{"id":28565,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-02-07T21:00:13.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":1572,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024."}],"balance_after":37697,"source":{"system":"sec-edgar","filing":"0001415889-25-003337","document":"form4a-02072025_040201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588925003337/form4a-02072025_040201.xml","form_type":"4/A","original_submission_date":"2024-02-20"}},{"id":28564,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D and CSO"}}],"security":"Common Stock, $0.01 par value","published_at":"2025-02-07T21:00:13.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":5900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024."}],"balance_after":36125,"source":{"system":"sec-edgar","filing":"0001415889-25-003337","document":"form4a-02072025_040201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588925003337/form4a-02072025_040201.xml","form_type":"4/A","original_submission_date":"2024-02-20"}},{"id":44468,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CMO, GLOBAL THERAPEUTICS"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-03-01T22:50:11.000Z","date":"2024-02-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":4914,"price":178.99,"value":879556.86,"ownership":{"direct":true},"balance_after":23259,"source":{"system":"sec-edgar","filing":"0001415889-24-006157","document":"form4-03012024_050305.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588924006157/form4-03012024_050305.xml","form_type":"4"}},{"id":45427,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CMO, GLOBAL THERAPEUTICS"}}],"security":"Option (Right to buy)","published_at":"2024-02-20T22:15:54.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":13868,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,775 on February 15, 2025, 7,775 on February 15, 2026, and 7,774 on February 15, 2027."}],"balance_after":13868,"derivative":{"exercise_price":0,"exercise_date":"2025-02-15","expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":13868},"source":{"system":"sec-edgar","filing":"0001415889-24-004421","document":"form4-02202024_050235.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588924004421/form4-02202024_050235.xml","form_type":"4"}},{"id":45426,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CMO, GLOBAL THERAPEUTICS"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-02-20T22:15:54.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":5792,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024."}],"balance_after":28173,"source":{"system":"sec-edgar","filing":"0001415889-24-004421","document":"form4-02202024_050235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588924004421/form4-02202024_050235.xml","form_type":"4"}},{"id":45425,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CMO, GLOBAL THERAPEUTICS"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-02-20T22:15:54.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":1844,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024."}],"balance_after":22381,"source":{"system":"sec-edgar","filing":"0001415889-24-004421","document":"form4-02202024_050235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588924004421/form4-02202024_050235.xml","form_type":"4"}},{"id":45424,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CMO, GLOBAL THERAPEUTICS"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-02-20T22:15:54.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":2138,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024."}],"balance_after":20537,"source":{"system":"sec-edgar","filing":"0001415889-24-004421","document":"form4-02202024_050235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588924004421/form4-02202024_050235.xml","form_type":"4"}},{"id":45423,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":11025,"kind":"person","name":"Thakkar Roopal","position":1,"cik":"0002004979","reported_name":"Thakkar Roopal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CMO, GLOBAL THERAPEUTICS"}}],"security":"Common Stock, $0.01 par value","published_at":"2024-02-20T22:15:54.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":8022,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024."}],"balance_after":18399,"source":{"system":"sec-edgar","filing":"0001415889-24-004421","document":"form4-02202024_050235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551152/000141588924004421/form4-02202024_050235.xml","form_type":"4"}}]}